Methods and compositions for treating dry eye, tear hyperosmolarity-induced pathological changes, and other ocular conditions

Abstract

The present disclosure is directed to compositions, formulations, and methods for treating diseases of the eye and other disorders. Specifically, d-MAPPS compositions, which may include d-MAPPS solutions (e.g., in liquid form and/or administered as eye drops), in addition to macromolecular proteins, growth factors, mesenchymal stem cells (MSC), can be used for topical application to the eye and treatment of, for instance, tear hyperosmolarity (TH), dry eye, dry eye disease, dry eye discomfort, tear hyperosmolarity, and tear hyperosmolarity-induced pathological changes in the eyes of patients. The d-MAPPS solutions can contain mesenchymal stem cells (MSC), MSC-derived exosomes (MSC-Exos), one or more MSC-sourced growth factors, and/or immunoregulatory proteins. In some embodiments, the d-MAPPS solutions can include a sterile de-cellularized human amniotic fluid (D-HAF). In embodiments, the d-MAPPS solutions are amenable to long-term storage without the loss of biological potency.

Dependencies are inferred from the claim text.